News

The technology is expected to be capable of enumerating, screening, and scoring billions of synthetically feasible, virtual compounds supporting the identification and optimization of potential new therapeutic candidates.

Keytruda has been approved to treat patients with BCG- unresponsive, high-risk NMIBC with carcinoma in situ (CIS) with or without papillary tumours who are ineligible for or have

SM-88 is one of the cancer metabolism-based therapies (CMBTs) that are being developed by Tyme Technologies. According to the company, CMBTs are investigational compounds that can potentially disrupt

The collaborations will explore the possibility and the potential of new therapies to treat challenging autoimmune, infectious and idiopathic diseases by leveraging SAB’s DiversitAb platform. SAB has developed

The European Medicines Agency’s (EMA) validation of the MAA confirms that the submission is sufficiently complete to begin the formal review process. “The EMA’s validation of Incyte’s Marketing

Reported to be the world’s largest independent funder of cancer research, Cancer Research UK will provide funding for the exploratory development of Bicycle’s BT7401 candidate through a phase

As per the supplemental New Drug Application (sNDA), AstraZeneca is seeking approval for Farxiga for its use in lowering the risk of cardiovascular (CV) death or the worsening

Under the terms of the agreement, Apollomics will be responsible for clinical development and commercialization in Greater China. The companies will also collaborate to advance the preclinical and

TCTC Group provides clinical operations, regulatory, personnel and medical services for full-service clinical studies and stand-alone clinical trials for biopharmaceutical companies throughout the world. The acquisition of TCTC